| For: | Kamrul-Hasan ABM, Pappachan JM, Ashraf H, Nagendra L, Dutta D, Kuchay MS, Shaikh S. Safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with type 2 diabetes mellitus fasting during Ramadan: a systematic review and meta-analysis. World J Methodol 2025; 15(4): 105478 [PMID: 40900863 DOI: 10.5662/wjm.v15.i4.105478] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v15/i4/105478.htm |
| Number | Citing Articles |
| 1 |
Tanveer Ashraf, Nader Lessan. GLP-1 receptor agonist adjunct therapy stabilises Ramadan dysglycaemia in insulin-treated diabetes: a CGM-based study. Diabetes Research and Clinical Practice 2026; 238 doi: 10.1016/j.diabres.2026.113369
|
| 2 |
Hafiza Valizada, Mihail Zilbermint. Severe Gastrointestinal Intolerance After Resuming Maintenance-Dose Semaglutide Following Ramadan-Related Treatment Interruption: A Case Report. Cureus 2026; doi: 10.7759/cureus.113026
|
| 3 |
Talal Muzaffar, Habib Steitieh, Khaled Khudadah, Muneera AlRandi, Guruprasad Subbarao, Shashikanth Chetty, Ahmed Shalaby, Amna Shaghouli. The efficacy and safety of once-daily oral semaglutide in adults with type 2 diabetes during Ramadan: A prospective observational study in Kuwait. Endocrine and Metabolic Science 2026; 22 doi: 10.1016/j.endmts.2026.100325
|